Life (Basel, Switzerland) · 2024
Effect of Continuous Intake of Lactobacillus salivarius WB21 on Tissues Surrounding Implants: A Double-Blind Randomized Clinical Trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Taniguchi Yusuke, Suzuki Nao, Kakura Kae, Tanabe Kazunari, Ito Ryutaro, Kashiwamura Tadahiro, Fujimoto Akie, Naito Marie, Yoneda Masahiro, Hanioka Takashi, Kido Hirofumi
Аннотация
OBJECTIVE: This study aimed to improve the health of peri-implant tissues through continuous intake of Lactobacillus salivarius WB21 (LSWB21) tablets.
METHODS: A double-blind, randomized controlled trial was conducted with 23 maintenance patients who had generally healthy oral peri-implant tissues. Participants were divided into a test group (n = 12) receiving LSWB21 tablets and a control group (n = 11) receiving placebos. All patients took one tablet three times daily for 2 months. Evaluation measures included modified Gingival Index (mGI), modified Plaque Index (mPI), modified Bleeding Index (mBI), salivary secretory IgA, and oral symptoms assessed at baseline, 1 month, and 2 months.
RESULTS: After 2 months, significant improvements in the mGI, mPI, and mBI were observed in the test group; significant improvement in the mPI was observed in the control group. Changes in the mGI over 2 months significantly differed between the groups (p = 0.038), and multiple regression analysis confirmed the effectiveness of LSWB21 in reducing the mGI (p = 0.034). Subjective symptoms such as bad breath in the test group and tongue symptoms in the control group also significantly improved.
CONCLUSION: Continuous intake of LSWB21 may be beneficial for stabilizing peri-implant tissue.
TRIAL REGISTRATION: UMIN000039392 (UMIN-CTR).
METHODS: A double-blind, randomized controlled trial was conducted with 23 maintenance patients who had generally healthy oral peri-implant tissues. Participants were divided into a test group (n = 12) receiving LSWB21 tablets and a control group (n = 11) receiving placebos. All patients took one tablet three times daily for 2 months. Evaluation measures included modified Gingival Index (mGI), modified Plaque Index (mPI), modified Bleeding Index (mBI), salivary secretory IgA, and oral symptoms assessed at baseline, 1 month, and 2 months.
RESULTS: After 2 months, significant improvements in the mGI, mPI, and mBI were observed in the test group; significant improvement in the mPI was observed in the control group. Changes in the mGI over 2 months significantly differed between the groups (p = 0.038), and multiple regression analysis confirmed the effectiveness of LSWB21 in reducing the mGI (p = 0.034). Subjective symptoms such as bad breath in the test group and tongue symptoms in the control group also significantly improved.
CONCLUSION: Continuous intake of LSWB21 may be beneficial for stabilizing peri-implant tissue.
TRIAL REGISTRATION: UMIN000039392 (UMIN-CTR).